Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432366 | 0.98 | KDM4E (0.45) | KDM4EPOLBGAAOPRM1ALDH1A1 | |
| SCHEMBL2658304 | 0.96 | ALDH1A1 (0.42) | KDM4EPOLBGAAOPRM1ALDH1A1 | |
| SCHEMBL498414 | 0.91 | ALDH1A1 (0.40) | KDM4EPOLBGAAALDH1A1CYP2A6 | |
| SCHEMBL10784403 | 0.82 | KDM4E (0.54) | KDM4EPOLBGAAOPRM1ALDH1A1 | |
| SCHEMBL497987 | 0.79 | KDM1A (0.39) | KDM4EPOLBGAAALDH1A1EPHX2 | |
| SCHEMBL6987167 | 0.79 | ALDH1A1 (0.39) | POLBALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL10985072 | 0.78 | RAB9A (0.41) | POLBALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL8669221 | 0.77 | RELA (0.43) | KDM4EALDH1A1MAPTSMN1; SMN2EPHX1 | |
| SCHEMBL2658432 | 0.75 | ALDH1A1 (0.39) | KDM4EOPRM1ALDH1A1CYP2A6OPRD1 | |
| Styrene SCHEMBL10832868 | 0.75 | ALDH1A1 (0.50) | KDM4EPOLBGAAALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| CN-102300550-A | Perfume systems | — | 2011-12-28 | — | — | CN | claimed |
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| CN-107669669-A | novel glucagon receptor antagonist | 症变治疗公司 | 2018-02-09 | — | — | CN | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| CN-101610995-B | Glucagon receptor antagonists | 症变治疗公司 | 2017-08-08 | — | — | CN | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KDM4E 4412/4885POLB 4486/4885GAA 541/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | KDM4E 4337/4885POLB 4518/4885GAA 419/4885 |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | KDM4E 3945/4885POLB 2980/4885GAA 2350/4885 |
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | KDM4E 4172/4885POLB 3756/4885GAA 3107/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KDM4E 4398/4885POLB 4502/4885GAA 557/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | KDM4E 4338/4885POLB 4495/4885GAA 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.